Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

Basit Öğe Kaydı
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorÖzatlı, Tahsin
dc.contributor.authorTürkmen, Esma
dc.contributor.authorÖztürk, Türkan
dc.contributor.authorÖzçelik, Melike
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorSevinç, Alper
dc.date.accessioned2021-11-20T10:10:03Z
dc.date.available2021-11-20T10:10:03Z
dc.date.issued2016
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Anabilim Dalıen_US
dc.description.abstractBackground: Prognostic factors and the standard treatment approach for gynaecological carcinosarco-mas have not yet been clearly defined. Although car-cinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly. Serous/clear cell and endometrioid components may be predictive fac-tors for the efficacy of adjuvant chemotherapy (CT) or radiotherapy (RT) or RT in patients with uterine and ovarian carcinosarcomas. Heterologous carcino-sarcomas may benefit more from adjuvant CT.Aims: We aimed to define the prognostic and predic-tive factors associated with treatment options in ovar-ian (OCS) and uterine carcinosarcoma (UCS).Study Design: Retrospective cross-sectional studyMethods: We retrospectively reviewed the medical re-cords of patients with ovarian and uterine carcinosar-coma from 2000 to 2013, and 127 women were includ-ed in this study (24 ovarian and 103 uterine). Patients admitted to seventeen oncology centres in Turkey be-tween 2000 and December 2013 with a histologically proven diagnosis of uterine carcinosarcoma with FIGO 2009 stage I-III and patients with sufficient data ob-tained from well-kept medical records were included in this study. Stage IV tumours were excluded. The pa-tient records were retrospectively reviewed. Data from 104 patients were evaluated for this study.Results: Age (>=70 years) was a poor prognostic factor for UCS (p=0.036). Pelvic±para aortic lymph node dis-section did not affect overall survival (OS) (p=0.35). Macroscopic residual disease was related with OS (p<0.01). The median OS was significantly longer in stage I-II patients than stage III patients (p=0.03). Adjuvant treatment improved OS (p=0.013). Adju-vant radiotherapy tended to increase the median OSen_US
dc.identifier.doi10.5152/balkanmedj.2016.151268en_US
dc.identifier.endpage524en_US
dc.identifier.issn2146-3123
dc.identifier.issn2146-3131
dc.identifier.issue5en_US
dc.identifier.pmid27761279en_US
dc.identifier.scopus2-s2.0-84989284795en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage517en_US
dc.identifier.trdizinid204560en_US
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TWpBME5UWXdNQT09
dc.identifier.urihttps://hdl.handle.net/20.500.14551/5485
dc.identifier.volume33en_US
dc.identifier.wosWOS:000384744100006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofBalkan Medical Journalen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240608_ID_Qen_US
dc.subjectCerrahien_US
dc.titlePredictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomasen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5485.pdf
Boyut:
823.81 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Balkan Medical Journal
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu